Scimega Blog Leveraging Canada For Quicker Oncology Site Start-Up

A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study. They were experiencing slow enrollment due to a scarcity of comparator arm naïve subjects in the U.S, where ...Read more...